Log In
BCIQ
Print this Print this
 

Brevibloc, esmolol HCl

  Manage Alerts
Collapse Summary General Information
Company Baxter International Inc.
DescriptionCardioselective adrenergic receptor beta 1 (ADRB1) antagonist
Molecular Target Adrenergic receptor beta 1 (ADRB1)
Mechanism of ActionAdrenergic receptor beta 1 (ADRB1) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationTachycardia
Indication DetailsTreat rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable.; Treat noncompensatory sinus tachycardia where, in the physician's judgment, the rapid heart rate requires specific intervention; Treat tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician's judgment such specific intervention is considered indicated.
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today